{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T22:36:24Z","timestamp":1717108584884},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":5180,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1999,1]]},"abstract":"<jats:p><jats:italic>The single\u2010dose effects of the cytochrome P\u2010450 inhibitors erythromycin and ketoconazole on the steady\u2010state pharmacokinetics and electrocardiographic repolarization pharmacodynamics of intranasal levocabastine, a potent and selective H<\/jats:italic><jats:sub>1<\/jats:sub>\u2010<jats:italic>receptor antagonist, were evaluated in healthy young male subjects. Two randomized, open\u2010label, placebo\u2010controlled, two\u2010way crossover studies were performed. Levocabastine nasal spray was administered as two sprays per nostril (0.05 mg\/spray) twice daily (for a total daily dose of 0.4 mg) for 6 days. On Day 7, a single dose of 0.2 mg was administered followed immediately by a single dose of either oral placebo, erythromycin 333 mg, or ketoconazole 200 mg. In all treatment groups, levocabastine was rapidly absorbed, with peak plasma concentrations reached at approximately 3 hours in the erythromycin study and 2.8 hours in the ketoconazole study. The mean terminal half\u2010life was approximately 45 and 44 hours, respectively. In both studies, mean steady\u2010state plasma concentrations and pharmacokinetics of levocabastine following the single doses of erythromycin or ketoconazole were not significantly different from corresponding values seen with the concomitant administration of the placebo. No clinically significant mean changes from baseline in QT or QT<jats:sub>c<\/jats:sub> (QT corrected for heart rate) intervals occurred in any of the treatment groups, and none of the subjects in either study experienced abnormally prolonged QT<jats:sub>c<\/jats:sub> intervals. Intranasal levocabastine was well tolerated, with no difference in the incidence of adverse events between treatment groups in either study; adverse events were generally mild in severity. Since levocabastine undergoes only minimal hepatic metabolism and is not a substrate for or an inhibitor of cytochrome P\u2010450, the likelihood of systemic drug interactions with drugs affecting the cytochrome P\u2010450 system is minimal<\/jats:italic>.<\/jats:p>","DOI":"10.1177\/00912709922007589","type":"journal-article","created":{"date-parts":[[2003,7,19]],"date-time":"2003-07-19T09:38:13Z","timestamp":1058607493000},"page":"76-85","source":"Crossref","is-referenced-by-count":12,"title":["Lack of Effect of Erythromycin and Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Steady\u2010State Intranasal Levocabastine"],"prefix":"10.1002","volume":"39","author":[{"given":"Luana","family":"Pesco\u2010Koplowitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Hassell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honghui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Wiesinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Witold","family":"Mechlinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Grover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Travers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01990945"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199550060-00009"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1358\/dof.1986.011.10.51907","article-title":"Levocabastine hydrochloride","volume":"11","author":"Bussche Vanden G","year":"1986","journal-title":"Drugs Future"},{"key":"e_1_2_1_5_2","first-page":"140","article-title":"Intranasal levocabastine provides fast and effective protection from nasal allergen challenge","volume":"34","author":"Bachert C","year":"1996","journal-title":"Rhinology"},{"key":"e_1_2_1_6_2","first-page":"25","article-title":"The effect of levocabastine nasal spray in nasal provocation tests","volume":"8","author":"Palma\u2010Carlos AG","year":"1988","journal-title":"Int J Clin Pharmacol Res"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)81233-4"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.2500\/105065893781976474"},{"key":"e_1_2_1_9_2","first-page":"429","article-title":"Safety and efficacy of topical levocabastine compared with oral terfenadine","volume":"72","author":"Bahmer FA","year":"1994","journal-title":"Ann Allergy"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(93)90040-M"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1994.tb00127.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1993.tb01110.x"},{"key":"e_1_2_1_13_2","first-page":"121","article-title":"Intranasal levocabastine for the treatment of seasonal allergic rhinitis: a multicentre, double\u2010blind, placebo\u2010controlled trial","volume":"33","author":"Dahl R","year":"1995","journal-title":"Rhinology"},{"key":"e_1_2_1_14_2","article-title":"Efficacy and safety of levocabastine nasal spray for seasonal allergic rhinitis","author":"Hampel FC","journal-title":"Am J Rhinol"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199529040-00002"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199121050-00005"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.135"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199427010-00001"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(95)02169-8"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/emj.6.1.63"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/jama.1993.03500120051025","article-title":"Terfenadine\u2010ketoconazole interaction: pharmacokinetic and electrocardiographic consequences","volume":"269","author":"Honig PK","year":"1993","journal-title":"JAMA"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/106002809402800226","article-title":"Drug\u2010induced torsades de pointes: a possible interaction of terfenadine and erythromycin (letter)","volume":"28","author":"Biglin KE","year":"1994","journal-title":"Ann Pharmacother"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90317-I"},{"key":"e_1_2_1_24_2","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1001\/archinte.1993.00410230129016","article-title":"Torsades de pointes associated with astemizole (Hismanal) therapy (letter)","volume":"153","author":"Goss JE","year":"1993","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1001\/jama.1991.03470170063023","article-title":"Torsades de pointes occurring in association with terfenadine use (letter)","volume":"266","author":"Mathews DR","year":"1991","journal-title":"JAMA"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03450210088038"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-6757(94)90029-9"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315505"},{"key":"e_1_2_1_29_2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1742-1241.1988.tb08578.x","article-title":"Torsade de pointes ventricular tachycardia associated with astemizole overdose","volume":"42","author":"Snook J","year":"1988","journal-title":"Br J Clin Pract"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a060277"},{"key":"e_1_2_1_31_2","volume-title":"Antibiotics in Laboratory Medicine.","author":"Edberg SC","year":"1986"},{"key":"e_1_2_1_32_2","volume-title":"Manual of Clinical Microbiology.","author":"Anhalt JP","year":"1991"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.1.110"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(91)90541-R"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03500120070028"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1994.tb04735.x"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F00912709922007589","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/00912709922007589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T23:10:36Z","timestamp":1698534636000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/00912709922007589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,1]]}},"alternative-id":["10.1177\/00912709922007589"],"URL":"https:\/\/doi.org\/10.1177\/00912709922007589","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,1]]}}}